Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

VNDA

Vanda Pharmaceuticals Inc.

Pharmaceutical Preparations · SIC 2834CIK 1347178Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$216.0M
Net Income FY2025
$(220.0M)
EPS (Basic, as reported)
$-3.74
Net Margin FY2025
-102.0%
ROE FY2025
-67.4%
Total Equity
$327.0M
Shares Out
60M
Business description

Vanda Pharmaceuticals Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 146 → 216 +4.4% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue146165193227248269254193199216
Cost of revenue——(21)(24)(23)(26)(24)(15)(11)(13)
Research & development(29)(39)(44)(49)(56)(75)(86)(77)(74)(109)
Selling, general & administrative(100)(124)(106)(130)(141)(124)(136)(113)(146)(238)
General & administrative——————————
Total operating expenses(165)(182)(171)(204)(221)(227)(248)(207)(239)(367)
Operating income(19)(17)222327426(14)(41)(151)
Interest & investment income——————————
Pre-tax income(18)(15)25293242116(23)(139)
Income tax expense000(87)(8)(9)(5)(4)(4)(82)
Net income(18)(16)25116233363(19)(220)
EPS — basic($0.41)($0.35)$0.50$2.17$0.43$0.60$0.11$0.04($0.33)($3.74)
EPS — diluted($0.41)($0.35)$0.48$2.11$0.42$0.58$0.11$0.04($0.33)($3.74)
Shares outstanding — basic (M)43455153545656575859
Shares outstanding — diluted (M)43455355555757585859

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.